Replimune Group, Inc. (REPL) NASDAQ

8.87

-0.1343(-1.49%)

Updated at June 02 03:26PM

Currency In USD

Replimune Group, Inc.

Address

500 Unicorn Park Drive

Woburn, MA 01801

United States of America (the)

Phone

781 222 9600

Website

https://www.replimune.com

Sector

Healthcare

Industry

Biotechnology

Employees

479

First IPO Date

July 20, 2018

Key Executives

Name	Title	Pay	Year Born
Sushil Patel	Chief Executive Officer & Director	1.06M	1971
Christopher Sarchi	Chief Commercial Officer	594,578	1971
Emily Luisa Hill	Chief Financial Officer	752,024	1980
Konstantinos Xynos	Chief Medical Officer	781,936	1966
Philip Astley-Sparke	Executive Chairman	960,520	1971
Andrew Schwendenman	Chief Accounting Officer & Treasurer	0	1976
Camilo Garcia	Chief Human Resource Officer	0	N/A
Shawn Glidden	Senior Vice President & General Counsel	0	N/A
Carolyn Trott	Senior Vice President of Quality Assurance	0	N/A
Nina Aragam	Senior Vice President of Portfolio Strategy & Program Management	0	N/A
Paul Bullock	Chief Manufacturing Officer & Framingham Site Head	0	N/A

Description

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.